NestléNutritionInstitute

Controversies in Critical Care Nutrition


Stephen A. McClave, MD
Professor of Medicine
Division of Gastroenterology, Hepatology, and Nutrition
University of Louisville, Louisville, KY

Presented on June 27, 2018

Disclosure

Financial Support for this presentation was provided by Nestlé Health Science. The views expressed herein are those of the presenter and do not necessarily represent Nestlé's views. The material herein is accurate as of the date it was presented, and is for educational purposes only and is not intended as a substitute for medical advice. Reproduction or distribution of these materials is prohibited.

Copyright 2018 Nestlé. All rights reserved.



Objectives



- To understand the quality of evidence in the literature supporting early enteral feeding in critical illness.
- To learn the clinical impact from loss of gut barrier defenses, immune dysregulation, and progression from a commensal microbiome to a virulent pathobiome.
- To appreciate new ways by which nutritional therapy can support the intestinal microbiome and promote a clinical pattern of recovery in an ICU setting.

Chaos in Critical Care Nutrition: How Important is Nutritional Rx?



PN



EN


"Recent large RCTs have not generated evidence that providing nutrition early in critical illness results in clinical benefits"

Weakness in Scientific Method

Why Most Published Research Findings
Are False
John P.A. loannidis

Truth of research findings related to its reproducibility by subsequent research trials or its Positive Predictive Value (PPV)

How Do We Trust Research Results?




High Quality Studies


- Large well-designed RCTs, appropriate meta-analyses of sound RCTs have highest PPV 10% of large RCTs will be discounted by subsequent trials 33% of good quality meta-analyses will be reversed
- Observational studies suffer from potential for confounding factors
 85% will be discounted by future studies
- Principles of clinical practice derived from all scientific information available
 No study totally reliable at exclusion of all others
 Incorporate findings if methodology sound, results plausible, supported by physiology₆

JPA loannidis [PLoSMedicine 2005;2(8):e124]

Documenting the Benefit of Nutritional Therapy

Recent large studies show no difference trophic vs full feeds, EN vs PN Mortality of ARDSNet Controls has decreased 70% → < 20% over 30 yrs As critical care improves, harder to tease out influence of each Rx modality





Outcome: Infections Early EN vs No Early EN (p=0.01) Early EN Delayed/None Events Total Events Study or Subgroup Total Weight M-H, Random, 95% Cl Year M-H, Random, 95% CI Sagar 1979 0.60 [0.17, 2.07] 1979 Moore 1986 3 32 31 0.32 [0.10, 1.08] 1986 9 3.3% 3.00 [0.13, 68.57] 1991 Sol roede r 1991 16 16 0.5% 0 Carr 1996 0 14 14 0.6% 0.14 [0.01, 2.53] 1996 Beier-Holgeiser 1996 2 30 14 30 2.5% 0.14 [0.04, 0.57] 1996 Singl 1998 22 7.6% 0.61 [0.30, 1.25] 1998 Minard 2000 15 6.6% 1.07 [D.49, 2.34] 2000 0.81 [0.64, 1.01] 2004 Malhotta 2004 54 100 100 20.9% 0.52 D 28, 0.96 2004 Kompai 2004 9 27 25 9.4% Peck 2004 13 17.7% 1.01 p.74, 1.39 2004 Ng rye r 2008 14 3.5% 0.50 p.15, 1.61 2008 Moses 2009 0.93 [0.61, 1.39] 2009 Chourdakis 2012 0.80 p.44, 1.49 2012 Total (95% CI) 358 0.74 [0.58, 0.93] Total eue ets 130 181 He terogeneity: $Tan^2 = 0.05$; Ch P = 19.58, df = 12 (P = 0.08); P = 39%Testfor oue talleffect Z = 2.54 (P = 0.01)

Nutrition Therapy Does Change Outcome

Early EN vs No Early EN

Infection 51.7%→36.3%, p=0.03

Controls: Intentional delay Do nothing (STD)

Clinical Guidelines


Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)

SA McClave, BE Taylor (JPEN 2016;40:159-211)

Outcome: Mortality Early EN vs No Early EN (p=0.05)


			Delayed None			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	MH, Random, 95% Cl Year	MH, Random, 95% Cl	
Sagar 1979	0	15	0	15		Not estimable 1979		
Moore 1986	1	32	2	31	2.3%	0.48 [0.05, 5.07] 1986	·	
Chiarelli 1990	0	10	0	10		Not estimable 1990		
Schroeder 1991	0	16		16		Not estimable 1991		
Eyer 1993	2	19	2	19	3.7%	100 [0.16, 6.38] 1993		
Beier-Holgersen 1996	2	30	4	30	4.9%	050 [0.10, 2.53] 1996	·	
Carr 1996	0	14	1	14	1.3%	0.33 [0.01, 7.55] 1996	• • • • • • • • • • • • • • • • • • • •	
Chuntrasakul 1996	1	21	3	17	2.7%	0.27 [0.03, 2.37] 1996		
Watters 1997	0	14	0	14		Not estimable 1997		
Singh 1998	4	21	4	22	8.2%	1.05 [0.30, 3.66] 1998		
Kompan 1999	0	14	1	14	1.3%	0.33 [0.01, 7.55] 1999	• • • •	
Minard 2000	1	12	4	15	3.0%	0.31 [0.04, 2.44] 2000	• • •	
Pupelis 2000	1	11	5	18	3.2%	033 [0.04, 2.45] 2000	• • •	
Pupelis 2001	1	30	7	30	3.1%	0.14 [0.02, 1.09] 2001	•	
Dverak 2004	0	7	0	10		Not estimable 2004		
Kompan 2004	0	27	1	25	1.3%	0.31 [0.01, 7.26] 2004		
Peck 2004	4	14	5	13	11.0%	0.74 [0.25, 2.18] 2004		
Malhotra 2004	12	100	16	100	26.5%	0.75 [0.37, 1.50] 2004		
Nauyen 2008	6	14	6	14	17.5%	100 (0.43, 2.35) 2008		
Moses 2009	3	29	3	30	5.6%	1.03 [0.23, 4.71] 2009		
Chaurdakis 2012	3	34	2	25	4.4%	1.10 [0.20, 6.12] 2012	-	
Total (95% CI)		469		467	100.0%	0.70 [0.49, 1.00]	•	
Total events	41		66					
Heterogeneity: Tau* = 0	1.00; Chi ² =	7.23.	d=15P=	0.95);	2 = 0%		01 02 05 1 2 5 10	
Test for overall effect: 2							0.1 0.2 0.5 1 2 5 10 Favors Early EN Favors Delayed Nor	


Mortality 14.1%→8.7%, p=0.05



Balance Between Physiologic States








Pattern of Recovery


Barrier Function, Symbiosis, Homeostasis

Pattern of Gut Sepsis
Permeability, Dysbiosis,
Immune Dysregulation



Gut Responses toCritical Illness

Alterations in Barrier Function



Loss function (mucus, tight junctions, defensins)
Proinflammatory signaling (gut sepsis)
Penetration of pancreatic enzymes (MOF)
Emergence of virulent pathobiome


Dysregulated

immune response

Autodigestion

Small Intestine in Normal Digestion

Small Intestine in Autodigestion



Toxic Lymph MOF₀


Commensal Signaling

Anti-Inflamm Pro-Inflamm Immune Dysregulation

MA Krezalek, JC Alverdy (Shock 2016;45:475) M Hayakawa (Dig Dis Sci 2011;56:2361)

immune response

Progression from Microbiome to Pathobiome



- Disappearance of commensals, loss of biodiversity
- Emergence of virulent pathobiome
- Infectious morbidity, antibiotic resistance, anastomotic dehiscence

Calculating Nutritional Risk Gives Management Direction


- **Nutrition risk Two Aspects Disease severity Nutritional status**
- Why assess nutrition risk? **Prognostic - Tolerance, difficulty Rx** May predict need to goal, benefit of Rx Impact urgency, dose, need for supp PN

- Ir	npaired nutritional status	Severity of disease (= requirement/stress-metabolism)			
Mild Score 1	Wt loss >5% in 3 mths Or Food intake <50-75% of normal requirement in preceding week.	Mild Score 1	Hip fracture (9). Chronic patients, in particular with acute complications: cirrhosis (11), COPD (12). Chronic hemodialysis, diabetes, mailgnant oncology.		
Moderate Score 2	Wt loss >5% in 2 mths Or BMI 18.5 - 20.5 + impaired general condition Or Food intake 25-50% of normal requirement in preceding week	Moderate Score 2	Major abdominal surgery (13-15). Stroke (16). Severe pneumonia, malignant hematology.		
Severe	Wt loss >5% in 1 mth (≈>15% in 3 mths (17)) Or BMI <18.5 + impaired general condition (17) or Food intake 0-25% of normal requirement in preceding week	Severe	Head injury (18, 19). Bone marrow transplantation (20). Intensive care patients (APACHE>10).		
Score:	+	Score:	- TOTAL SCORE:		

Age >70 yrs : Add 1 point

Score ≥3 Consider EN/PN Score ≥5 High risk





Is Trophic Underfeeding Effective?




Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury

The EDEN Randomized Trial

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network*

Context The amo unknown.

Objective To dete crease ventilator-free




Eden Omega Trial ALI/ARDS patients on MV ¹
Trophic 20cc/hr (n=508) vs Full feeds (n=492)
No difference: Mortality, vent-free days, MOF, infection

PERMIT Trial Permissive Underfeeding in Mix ICU ²
Underfeed 46% (n=894) vs Full feed 71% (n=446)
No difference: Infection, ICU LOS, ICU/Hosp mortality

Value of EN Due to Physiologic Response

Critical Care Medicine



Non-Nutritional:

Trophic dose EN may be OK Nutritional:

Probably need full dose EN

Non-Nutrition benefits – Seen in all patients

Gastrointestinal responses

Trophic on gut integrity

Gut/lung axis of inflamm

Reduced bact virulence

Commensal bacteria Secretory IgA, GALT tissue

Immune responses

Modulate regulatory cells Promote Th-2 >Th-1 lymphocytes Maintain MALT tissue

Metabolic responses

Incretin to ↑ insulin sens Reduce hyperglycemia (AGES)

Nutrition benefits – Seen in high risk patients

Protein, calories

Micronutrients, anti-oxidants

Maintain LBM

Stimulate protein synthesis

14

S McClave, R Martindale, T Rice, D Heyland (CCM 2014;42:2600)

Nutrirea-2 Trial: Impact of Aggressive EN

Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)

Jean Reignler, Jolie Boisramé-Helins, Laurent Brisard, Jean-Baptiste Lascarrou, All Alt Hassaln, Nadia Anguel, Laurent Argaud, Karim Asehnaune, Pierre Asfar, Erddéric Bellin; Vlad Botoc, Aurre Bretagnol, Hoang-Nam Bui, Emmanuel Canet, Daniel Da Silva, Michael Darmon, Vincent Das, Jérôme Devaquet, Milchel Dithre, Frédérique Ganster, Mait & Garrovste-Orgeos, Stéphana Gaudy, Olivier Gootser, Claude Guérin, Bertrand Guidet, Christophe Gigitton, Jean-Etienne Herbrocht, Jean-Claude Lacherade, Philippa Letocut, Frédéric Mantino, Vigni e Massine, Ermanuelle Mercier, Jean-Paul Mira, Soad Nexis, Goal Piton, Jean-Pierre Quenot, Jack Richecorus, Jean-Philippa Rigaud, René Robert, Mathaelle Rolle, Carole Schwebel, Michel Sirodat, François Tintumer, Didier Thévenin, Bruno Girmudeau, Arnéle Le Gauge, for the NUTRIREA-2 Trial Investigators and the Clinical Research in Intensive Care and Sepsis (CRICS) group

- Third largest PRCT in clinical nutrition (n=2400)
 EN vs PN in MICU adults on MV in septic shock
 Elderly (63 yrs), ICU LOS (9-10 days), high mortality rate (35%)
 Groups got same calories (18-19 kcal/kg/d), protein (0.7-0.8 g/kg/d)
 Key issue EN start w/in 24 hrs of MV, advance to goal w/in 24 hrs
- Differences minimized by short duration of Rx in EN (6 days EN)
 Crossover of PN group to EN after 3 days (aver 4 days PN)
- Results: No difference in outcomes
 Bowel Ischemia in 19 EN pts vs 5 PN pts (p<0.05)


15


Five Reasons for Slow Ramp-up Over First Week


Week

ICU

- Risk of bowel ischemia in pts with hemodynamic instability ¹
- Overfeeding in ICU pts can occur when formula is added to hepatic endogenous glucose production ²
- Risk of refeeding syndrome in pts with hypophosphatemia ³
- Underfeeding supports Autophagy
- Gauge tolerance as rate of infusion increased








- ¹ J Reignier (Lancet 2018;391:133)
- ² V Fraipont, JC Prieser (JPEN 2016;37:705-13)
- ³ GS Doig (Lancet Respir Med 2015; 3: 943-52) 16


Pushing Protein: From Sarcopenia to Anabolic Resistence and Exercise




Reaching protein goals >> energy goals
Pushing dose to higher range 1.2-2.0 gm/kg/day



Important concept or jumping on a bandwagon?






MJ Allingstrup (Clin Nutr 2012;31:462)
Zusman (Crit Care 2016;20:367)

Pushing Protein

Is there a ceiling on protein incorporation into muscle?



Anabolic resistance 1

Splanchnic sequestration of AAs


Availability of AAs to muscle, other organs

Blunted anabolic response to AA provision

Worsened by insulin resistence, inflammation,

critical illness, age, # satellite cells, disuse

↑ Protein may overcome anabolic resistance



Elderly particularly susceptible: ²

↑ Baseline loss musc mass

↓ Recovery musc fxn after disuse

↑ Anabolic resistence to AA

↑ Levels of protein needed for pos NB

18

¹Shad (AmJPhysEndocrMetab 2016;311:E803) ²Dickerson (JPEN 2015;39:759) ³Koekkoek (ClinNutr 2018) ⁴ M Nicolo (JPEN 2016;40:45)

- Protein doses high enough? Intermittent > continuous?
- Importance of exercise Start early in critical illness
 Time exercise with protein provision
- Adjust for level of function

Awake alert - Safe ambulation

Debilitated - ↑Time in chair, passive range-of-motion exercises


Altered MS, shock - Continuous passive motion (CPM) device


Neuromuscular electrical stimulation (NIMES)

What lessons can we learn from body builders?

BCAAs, HMB, Vit D, creatine, ALA, fish oil

Pushing Protein





Wischmeyer (Crit Care 2017;21:316) Hanna (JPEN 2015;39:273)


Should We Provide Micronutrient Supplements?




Three schools of thought: Measure levels, correct deficiencies

Empirically provide physiologic doses

Provide supraphysiologic doses



Micronutrient Supplementation



	Antioxid	tents	stand	and		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M.H. Random, 95% CI	M.H. Random, 95	N CI
Andrews, 2011	84	251	84	251	24.5%	1.00 (0.78, 1.28)	+	
Kuldinski, 1991	0	8		9	0.2%	0.07 [0.00, 0.98]	-	
Mishra, 2007	11	18	15	22	7.7%	0.90 [0.56, 1.43]		
Crimi, 2004	49	112	76	112	24.7%	0.64 (0.50, 0.82)		
Angstwurm, 1999	7	21	11	21	3.2%	0.64 (0.31, 1.32)		Mortality
Angstwurm, 2007	46	116	81	122	18.9%	0.79 (0.60, 1.06)		Mortality'
Forceville, 2007	14	31	13	29	5.4%	1.01 [0.58, 1.76]		,
Zimmerman, 1997	3	20		20	1.3%	0.38 [0.12, 1.21]		
Preiser, 2000		20	6	17	2.5%	1.13 (0.49, 2.62)		-
Valenta, 2011	19	75	24	75	8.5%	0.79 [0.48, 1.32]		
Manzanares, 2011	3	20 20 75 15 33 11	5	16	1.1%	0.64 (0.18, 2.22)		
Young, 1996	4	33	9	35	1.5%	0.47 (0.16, 1.38)		
Berger, 2007	1	11	1	10	0.2%	0.91 (0.07, 12.69)	-	
Berger 2001a	2	9	1	12	0.3%	2.67 [0.28, 25.04]		
Berger 2001b	0	11	1	12	0.2%	0.38 (0.02, 8.04)	-	
Schneider, 2011	6	29	6	29	1.7%	1.00 [0.37, 2.74]		-
Total (95% CI)		780		792	100.0%	0.80 [0.70, 0.92]	•	
Total events	257		329				6 as 6 6	7 19 S
Heterogeneity: Tau*:	0.00; Chi	*= 15.5	6, df = 15	P=0	41), F= 4	1%	01 02 05 1 2	5 10
Test for overall effect	Z= 3.27 (P = 0.00	21)					s standard

ASPEN/SCCM: Empiric Rx ¹
ESPEN Crit Care: Empiric Rx,
Measure Vit D ²
CCPGs: Do not rec Empiric Rx
(2015 reversed 2013 rec) ³

¹ SA McClave (JPEN 2016;40:159) ² M Berger (Clin Nutr online Jul 20, 2018 ESPEN 2018 Crit Care Guidelines)³ D Heyland (criticalcarenutrition.com Dec 2016) ⁴ M Berger (Clin Nutr 2005;24:172)

Should PN be Used More in the Hospital Setting?

Trial of the Route of Early Nutritional Support in Critically Ill Adults

Sheila E. Harvey, Ph.O., Francesca Parrott, M.Sci., David A. Harrison, Ph.D., Danielle E. Bear, M.Res., Elia Segaran, M.Sc., Richard Beale, M.B., B.S., Goff Bellingan, M.D., Richard Leonard, M.B., B.Chir., Michael G. Mythen, M.D., and Kathryn M. Rowan, Ph.D., for the CALORIES Trial Investigators*



- CALORIES Trial ¹ EN vs PN x 5 days in 2400 mixed ICU pts (80% goal feeds)
 No difference in outcomes
- NUTRIREA-2 Trial ² EN vs PN x 5-6 days in 2410 MICU pts in septic shock No difference in outcomes
- Impact: Under controlled conditions, high risk patients, PN can = EN
 EN still preferred over PN, but should lower threshold to use PN

SCCM

ASPEN

Initiation of PN



ESPEN

Critical Care Nutrition

□ SCCM/ASPEN 2016:

Exclusive PN (Low Risk) – Withhold PN over first week
Exclusive PN (High Risk) – Initiate PN ASAP
Supplemental PN – Withhold supp PN for 7-10 days (all pts)

Canadian CPGs 2015:

Exclusive PN (Low Risk) – Do not recommend PN Exclusive PN (High Risk) – Consider PN esp if malnourished Supplemental PN – Do not use in unselected patients

ESPEN 2018:

Use early low dose PN in malnourished pts EN not feasible Supplemental PN – Use case-by-case first week if EN < full dose

Comment: Insufficient EN defined <60% goal requirements</p>

Does Current Nutritional Rx Support the Microbiome?


- EN less inflammation than PN ^{1,2}
 Both result in relative nutrient deprivation
- Blenderized whole food formula vs polymeric (Mouse model) ³

Reduced systemic inflammation (IL-6 levels)
Greater biodiversity

↓Enterobacteriaceae, ↑Commensals

↑Beneficial anti-inflamm (orgs) compounds

Strategies to promote commensalism ^{4,5}
 Judicious Abx, opioids, serum bovine IgG
 Soluble fiber, PEG-phosphate
 Fecal microbial transplant (FMT)




¹Feng, Teitelbaum (Ann NY Acad Sci 2012;1258:71) ²Ralls, Teitelbaum (Surg 2015;157:732) ³Yeh, Morowitz (ASPEN CNW 2018 Abstr #2832646) ⁴ Morowitz (Surg Clin N Amer 2011;91:711) ⁵ Alverdy (CurrOpinClinNutrMetabCare 2005;8:205) ²⁴

Rationale for FMT in ICU

Clinical impact

Lose 90% comensals in 6 hrs, loss of biodiversity, emergence of virulent pathobiome Antibiotic resistant orgs, sepsis, anastomotic dehiscence, toxic lymph, MOF



Krezalek, Alverdy (Shock 2016;45:475) Morowitz, Alverdy (Ann Surg 2011; 253:1094) Zaborin, Alverdy (Am J Phys Gastroint Liver Physiol 2017;312:G112)

FMT in ICU


Delivery issues 1

Cecum > rectum 90 vs 63%

Southern > Northern route (86 vs 74%)

Second > first FMT (83 vs 62%)





- Comercial products from fully vetted donors ² Stool studies (C+S, O+P, C Diff, VRE, MRSA, norovirus) Serology (HIV, RPR, Hep A/B/C, CMV, EBV) Clinical (no Abx, incarceration, illicit drugs, tattoos)
- Lyophilized powder vs sterile fecal filtrate transfer (FFT) ³
 Bacterial components, bacterial phages, no live orgs
 Fresh/frozen vs lyophilized powder (83-100% vs 73-78%)



Experience with FMT in the ICU


Patient	Presentation	Concomitant Rx	FMT	Recovery
16 y.o. Female ⁷	Trauma, TBI,	Dexamethasone	Day 72	2 Days
	intractable diarrhea,	Antibiotics	Donor feces	↓ Fever
	AAA enterocolitis	Probiotics	(Mother)	↓ Diarrhea
			Cecal infusion	
29 y.o. Female ⁹	SIRS, intractable	Antibiotics	Day 20	1 Day
	diarrhea, septic shock	Probiotics	Donor feces	↓ Fever
	(H/O UC, colectomy)	10.	per NE tube	↓ Diarrhea
44 <u>y.o</u> . Female ⁵	Septic shock,	Antibiotics	Day 30	2 Days
	intractable diarrhea,	Probiotics	Donor feces	↓ Sepsis
	s/p partial	ECMO, CRRT	(Brother)	7 Days
	gastrectomy/vagotomy		per ND tube	↓ Diarrhea
65 <u>y.o</u> . Male ⁸	Cerebral hemorrhage,	Antibiotics	Day 20	1 Day
	MODS, septic shock,	C	Donor feces	↓ Fever
	intractable diarrhea		(Grad student)	7 Days
			Sterile-filtered	↓ Diarrhea
			pathogen-free	
			feces per NG	
			tube	
84 <u>y.o</u> . Male ⁸	Cerebral infarct,	Antibiotics	Day 7	1 Day
	MODS, septic shock,	Probiotics	Donor feces	↓ Fever
	intractable diarrhea		(Grad student)	7 Days
			Sterile-filtered	↓ Diarrhea
			pathogen-free	
			feces per NG	
			tube	

Phases of Critical Illness









Questions?

Nutrition-related resources and tools are available from Nestlé Nutrition Institute: nestlenutrition-institute.org

Visit MyCE at
MyCEeducation.com
Offering CE to dietitians and nurses